利好突袭！深夜暴涨！

Core Viewpoint - The article discusses the recent fluctuations in the U.S. stock market, focusing on the anticipated interest rate decisions by the Federal Reserve and the significant stock price movements of certain companies in the biotechnology sector. Group 1: Market Overview - As of December 8, U.S. stock indices showed mixed performance, with the Dow Jones down 0.19%, S&P 500 down 0.1%, and Nasdaq up 0.05% [2][3]. - The market is anticipating a 25 basis point rate cut by the Federal Reserve, with a probability of 89.6% according to the CME FedWatch Tool [2][4]. Group 2: Federal Reserve Insights - Nomura's report suggests that the Federal Reserve is likely to cut rates by 25 basis points in December, with some hawkish members expected to oppose this decision [4]. - Morgan Stanley has revised its prediction, now expecting a rate cut after the December 9-10 policy meeting, previously having delayed this expectation to 2026 due to strong employment data [4]. Group 3: Stock Performance - Wave Life Sciences saw a significant stock increase of 106.19% after announcing positive mid-stage trial results for its obesity treatment WVE-007, which showed improvements in body composition [5][7]. - Structure Therapeutics experienced a stock surge of 121.99%, attributed to a mid-stage clinical trial showing an 11.3% reduction in body weight for its obesity treatment candidate [8].